Session » Muscle Biology, Myositis & Myopathies (0955–0959)
-
Abstract Number: 0955
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
-
Abstract Number: 0956
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
-
Abstract Number: 0957
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
-
Abstract Number: 0958
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
-
Abstract Number: 0959
Altered Gut Microbiome in Dermatomyositis